The advent of cytotoxic T-lymphocyte-associated protein 4 inhibitors (CTLA4 inhibitors) and programmed death ligand 1 inhibitors (PD-1 inhibitors) has completely revolutionized the management and treatment of various cancers and especially improved the systemic treatment of advanced melanoma (6). Here, CTLA4 is linked to melanoma.